First Time Loading...

Chinook Therapeutics Inc
NASDAQ:KDNY

Watchlist Manager
Chinook Therapeutics Inc Logo
Chinook Therapeutics Inc
NASDAQ:KDNY
Watchlist
Price: 40.39 USD Market Closed
Updated: May 8, 2024

Chinook Therapeutics Inc
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Chinook Therapeutics Inc
Operating Income Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Chinook Therapeutics Inc
NASDAQ:KDNY
Operating Income
-$251.6m
CAGR 3-Years
-57%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Operating Income
$16.6B
CAGR 3-Years
8%
CAGR 5-Years
7%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Operating Income
$8.7B
CAGR 3-Years
24%
CAGR 5-Years
1%
CAGR 10-Years
3%
Amgen Inc
NASDAQ:AMGN
Operating Income
$7.1B
CAGR 3-Years
-7%
CAGR 5-Years
-7%
CAGR 10-Years
2%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Operating Income
$3.8B
CAGR 3-Years
10%
CAGR 5-Years
42%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Operating Income
$4B
CAGR 3-Years
0%
CAGR 5-Years
10%
CAGR 10-Years
17%

See Also

What is Chinook Therapeutics Inc's Operating Income?
Operating Income
-251.6m USD

Based on the financial report for Jun 30, 2023, Chinook Therapeutics Inc's Operating Income amounts to -251.6m USD.

What is Chinook Therapeutics Inc's Operating Income growth rate?
Operating Income CAGR 5Y
-19%

Over the last year, the Operating Income growth was -192%. The average annual Operating Income growth rates for Chinook Therapeutics Inc have been -57% over the past three years , -19% over the past five years .